{"id":"favipiravir","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"J05AX27","category":"atc"},{"label":"Active","category":"status"},{"label":"Influenza","category":"indication"},{"label":"Influenza caused by pandemic influenza virus","category":"indication"},{"label":"Toyama Chemical Co., Ltd.","category":"company"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":1208.51,"date":"","count":490,"signal":"Off label use","source":"DrugCentral FAERS","actionTaken":"Reported 490 times (LLR=1209)"},{"llr":104.147,"date":"","count":38,"signal":"Drug ineffective for unapproved indication","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=104)"},{"llr":86.773,"date":"","count":15,"signal":"Rhinocerebral mucormycosis","source":"DrugCentral FAERS","actionTaken":"Reported 15 times (LLR=87)"},{"llr":73.035,"date":"","count":18,"signal":"Systemic candida","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=73)"}],"commonSideEffects":[],"contraindications":["Pregnancy, function"]},"trials":[],"aliases":[],"company":"Toyama Chemical Co., Ltd.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FAVIPIRAVIR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:33:01.405914+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:33:06.711623+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FAVIPIRAVIR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:33:07.326233+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: RNA-directed RNA polymerase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:33:08.565538+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL221722/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:33:08.181197+00:00"}},"allNames":"avigan","offLabel":[],"synonyms":["favipiravir","avigan","T-705"],"timeline":[{"date":"2014-03-24","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Toyama Chemical Co., Ltd.)"}],"aiSummary":"Avigan (Favipiravir) is a small molecule antiviral medication originally developed by Toyama Chemical Co., Ltd. It is used to treat influenza and influenza caused by pandemic influenza virus. The exact mechanism of action is not fully understood, but it is believed to work by inhibiting viral RNA polymerase. Avigan is patented and its commercial status is not off-patent. Key safety considerations include potential liver and kidney damage.","approvals":[{"date":"2014-03-24","orphan":false,"company":"Toyama Chemical Co., Ltd.","regulator":"PMDA"}],"brandName":"Avigan","ecosystem":[{"indication":"Influenza","otherDrugs":[{"name":"baloxavir marboxil","slug":"baloxavir-marboxil","company":"Genentech Inc"},{"name":"formaldehyde","slug":"formaldehyde","company":""},{"name":"oseltamivir","slug":"oseltamivir","company":"Roche"},{"name":"peramivir","slug":"peramivir","company":"Biocryst"}],"globalPrevalence":null},{"indication":"Influenza caused by pandemic influenza virus","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Favipiravir is a pyrazine carboxamide derivative that acts as a viral RNA-dependent RNA polymerase inhibitor, specifically targeting the L protein of the influenza virus, which is essential for viral replication."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4887","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FAVIPIRAVIR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FAVIPIRAVIR","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:24:44.433033","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:33:09.812987+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"enfuvirtide","drugSlug":"enfuvirtide","fdaApproval":"2003-03-13","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"maraviroc","drugSlug":"maraviroc","fdaApproval":"2007-08-06","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"maribavir","drugSlug":"maribavir","fdaApproval":"2021-11-23","patentExpiry":"Oct 27, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"letermovir","drugSlug":"letermovir","fdaApproval":"2017-11-08","patentExpiry":"Jan 18, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ibalizumab","drugSlug":"ibalizumab","fdaApproval":"2018-03-06","relationship":"same-class"},{"drugName":"tecovirimat","drugSlug":"tecovirimat","fdaApproval":"2018-07-13","patentExpiry":"Sep 4, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"baloxavir marboxil","drugSlug":"baloxavir-marboxil","fdaApproval":"2018-10-24","patentExpiry":"Sep 25, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fostemsavir","drugSlug":"fostemsavir","fdaApproval":"2020-07-02","patentExpiry":"Nov 19, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"favipiravir","indications":{"approved":[{"name":"Influenza","source":"DrugCentral","snomedId":6142004,"regulator":"FDA"},{"name":"Influenza caused by pandemic influenza virus","source":"DrugCentral","snomedId":719865001,"regulator":"FDA"}],"offLabel":[{"name":"Coronavirus infection","source":"DrugCentral","drugName":"FAVIPIRAVIR","evidenceCount":675,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"enfuvirtide","brandName":"enfuvirtide","genericName":"enfuvirtide","approvalYear":"2003","relationship":"same-class"},{"drugId":"maraviroc","brandName":"maraviroc","genericName":"maraviroc","approvalYear":"2007","relationship":"same-class"},{"drugId":"maribavir","brandName":"maribavir","genericName":"maribavir","approvalYear":"2021","relationship":"same-class"},{"drugId":"letermovir","brandName":"letermovir","genericName":"letermovir","approvalYear":"2017","relationship":"same-class"},{"drugId":"ibalizumab","brandName":"ibalizumab","genericName":"ibalizumab","approvalYear":"2018","relationship":"same-class"},{"drugId":"tecovirimat","brandName":"tecovirimat","genericName":"tecovirimat","approvalYear":"2018","relationship":"same-class"},{"drugId":"baloxavir-marboxil","brandName":"baloxavir marboxil","genericName":"baloxavir marboxil","approvalYear":"2018","relationship":"same-class"},{"drugId":"fostemsavir","brandName":"fostemsavir","genericName":"fostemsavir","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05648448","phase":"PHASE2","title":"A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2023-02-22","conditions":["Influenza","Influenza, Human"],"enrollment":3000,"completionDate":"2027-01-01"},{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":["COVID-19"],"enrollment":3800,"completionDate":"2027-01"},{"nctId":"NCT06024421","phase":"PHASE1","title":"Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2024-05-14","conditions":["Infectious Disease","Pharmacology"],"enrollment":39,"completionDate":"2027-11"},{"nctId":"NCT06212336","phase":"PHASE2,PHASE3","title":"ISTH/ANRS 0409s INTEGRATE Lassa Fever Study","status":"RECRUITING","sponsor":"Irrua Specialist Teaching Hospital","startDate":"2025-05-02","conditions":["Lassa Fever"],"enrollment":1755,"completionDate":"2027-06"},{"nctId":"NCT04746183","phase":"PHASE1,PHASE2","title":"AGILE (Early Phase Platform Trial for COVID-19)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2020-07-03","conditions":["Covid19"],"enrollment":600,"completionDate":"2026-07-31"},{"nctId":"NCT02329054","phase":"PHASE2","title":"Efficacy of Favipiravir Against Ebola (JIKI)","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2014-12","conditions":["Ebola Virus Disease"],"enrollment":126,"completionDate":"2015-09"},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":["COVID-19"],"enrollment":192,"completionDate":"2021-08-23"},{"nctId":"NCT06488300","phase":"PHASE2","title":"Assessing Antiviral Treatments in Early Symptomatic RSV","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2024-07-25","conditions":["Respiratory Syncytial Virus","Respiratory Syncytial Virus, Human"],"enrollment":1000,"completionDate":"2027-01-01"},{"nctId":"NCT06860334","phase":"PHASE2","title":"UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF","status":"NOT_YET_RECRUITING","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-07-01","conditions":["Crimean-Congo Hemorrhagic Fever"],"enrollment":378,"completionDate":"2028-08-31"},{"nctId":"NCT02739477","phase":"PHASE2","title":"Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen","status":"TERMINATED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2016-04","conditions":["Ebola Virus Survivor"],"enrollment":2,"completionDate":"2016-08"},{"nctId":"NCT04784559","phase":"PHASE3","title":"Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection","status":"TERMINATED","sponsor":"PharmaMar","startDate":"2021-06-04","conditions":["COVID-19 Infection"],"enrollment":205,"completionDate":"2023-03-01"},{"nctId":"NCT04600895","phase":"PHASE3","title":"The Prevent Severe COVID-19 (PRESECO) Study","status":"COMPLETED","sponsor":"Appili Therapeutics Inc.","startDate":"2020-11-30","conditions":["Covid19"],"enrollment":1187,"completionDate":"2021-10-20"},{"nctId":"NCT06223984","phase":"PHASE4","title":"Combined Use of Immunoglobulin and Pulse Steroid Therapies in Severe Covid-19 Patients","status":"COMPLETED","sponsor":"Konya City Hospital","startDate":"2020-03-30","conditions":["Pulse Steroid and Immunoglobulins Drugs in Covid 19 Patients"],"enrollment":178,"completionDate":"2020-11-14"},{"nctId":"NCT05940545","phase":"PHASE1,PHASE2","title":"UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF","status":"UNKNOWN","sponsor":"Liverpool School of Tropical Medicine","startDate":"2023-07-12","conditions":["CCHF"],"enrollment":24,"completionDate":"2023-12-31"},{"nctId":"NCT04727775","phase":"","title":"Antiviral Drugs on the Treatment of SARS-CoV-2","status":"COMPLETED","sponsor":"Astana Medical University","startDate":"2020-12-01","conditions":["Complication of Medical Care","Pneumonia, Viral"],"enrollment":150,"completionDate":"2023-07-25"},{"nctId":"NCT05502081","phase":"PHASE4","title":"Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients","status":"COMPLETED","sponsor":"Mansoura University Hospital","startDate":"2022-09-02","conditions":["COVID-19"],"enrollment":265,"completionDate":"2022-12-28"},{"nctId":"NCT05774405","phase":"PHASE2","title":"Short-term Effects of Transdermal Estradiol on Female COVID-19 Patients","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2020-07-01","conditions":["COVID-19","Hormone Replacement Therapy"],"enrollment":9169,"completionDate":"2021-07-31"},{"nctId":"NCT04918927","phase":"PHASE2","title":"Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2021-10-12","conditions":["Covid19"],"enrollment":120,"completionDate":"2023-03-21"},{"nctId":"NCT04613271","phase":"PHASE3","title":"Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia","status":"COMPLETED","sponsor":"Ina-Respond","startDate":"2020-10-15","conditions":["Infectious Disease","SARS-CoV Infection","Covid19"],"enrollment":130,"completionDate":"2021-11-08"},{"nctId":"NCT04448119","phase":"PHASE2","title":"Control of COVID-19 Outbreaks in Long Term Care","status":"TERMINATED","sponsor":"Appili Therapeutics Inc.","startDate":"2020-10-16","conditions":["COVID-19","SARS-CoV-2"],"enrollment":67,"completionDate":"2021-10-30"},{"nctId":"NCT05187793","phase":"PHASE3","title":"Study of Efficacy of Different Treatment Regimens of Olokizumab","status":"UNKNOWN","sponsor":"R-Pharm","startDate":"2021-07-08","conditions":["COVID-19"],"enrollment":198,"completionDate":"2023-04"},{"nctId":"NCT04907682","phase":"PHASE2","title":"Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever","status":"COMPLETED","sponsor":"Bernhard Nocht Institute for Tropical Medicine","startDate":"2021-07-30","conditions":["Lassa Fever"],"enrollment":40,"completionDate":"2022-11-17"},{"nctId":"NCT05279235","phase":"PHASE3","title":"Efficacy and Safety of JT001 (VV116) Compared With Favipiravir","status":"TERMINATED","sponsor":"Shanghai Vinnerna Biosciences Co., Ltd.","startDate":"2022-03-14","conditions":["Moderate to Severe COVID-19"],"enrollment":290,"completionDate":"2022-12-15"},{"nctId":"NCT04501783","phase":"PHASE3","title":"Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2020-05-20","conditions":["COVID-19"],"enrollment":168,"completionDate":"2020-08-04"},{"nctId":"NCT04499677","phase":"PHASE2","title":"FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-09-24","conditions":["COVID-19"],"enrollment":240,"completionDate":"2022-01-17"},{"nctId":"NCT04940871","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Favipiravir-HU","status":"TERMINATED","sponsor":"University of Pecs","startDate":"2021-11-25","conditions":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)"],"enrollment":1,"completionDate":"2021-11-29"},{"nctId":"NCT04600999","phase":"PHASE3","title":"Clinical Trial of Favipiravir Treatment of Patients With COVID-19","status":"COMPLETED","sponsor":"University of Pecs","startDate":"2020-10-07","conditions":["SARS-CoV-2 Infection"],"enrollment":14,"completionDate":"2020-12-28"},{"nctId":"NCT05595824","phase":"PHASE3","title":"Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2021-12-01","conditions":["COVID-19"],"enrollment":240,"completionDate":"2022-03-11"},{"nctId":"NCT04346628","phase":"PHASE2","title":"Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-07-12","conditions":["Sars-CoV2","COVID-19"],"enrollment":149,"completionDate":"2021-04-16"},{"nctId":"NCT05417997","phase":"PHASE3","title":"Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients","status":"COMPLETED","sponsor":"RAAS Nutritionals, LLC","startDate":"2021-05-29","conditions":["COVID-19 Respiratory Infection","FLU","Cold; Influenza","Bacterial Pneumonia","COVID-19 Pneumonia"],"enrollment":71,"completionDate":"2021-12-02"},{"nctId":"NCT05155527","phase":"PHASE2","title":"Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2022-02-10","conditions":["COVID-19"],"enrollment":200,"completionDate":"2022-06"},{"nctId":"NCT04475991","phase":"PHASE2","title":"Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults","status":"TERMINATED","sponsor":"Hospital General de México Dr. Eduardo Liceaga","startDate":"2021-07-13","conditions":["COVID-19"],"enrollment":19,"completionDate":"2022-03-25"},{"nctId":"NCT04718285","phase":"PHASE2","title":"Investigation the Effect of Montelukast in COVID-19","status":"UNKNOWN","sponsor":"Bahçeşehir University","startDate":"2021-05-15","conditions":["COVID-19","SARS-CoV-2"],"enrollment":380,"completionDate":"2022-06-01"},{"nctId":"NCT04358549","phase":"PHASE2","title":"Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19","status":"COMPLETED","sponsor":"Fujifilm Pharmaceuticals U.S.A., Inc.","startDate":"2020-04-17","conditions":["COVID-19"],"enrollment":50,"completionDate":"2020-10-30"},{"nctId":"NCT04529499","phase":"PHASE3","title":"Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients","status":"TERMINATED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2020-08-22","conditions":["Covid19"],"enrollment":353,"completionDate":"2021-01-27"},{"nctId":"NCT05222113","phase":"","title":"OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA","status":"COMPLETED","sponsor":"Bernadette Dian Novita, MD.,PhD","startDate":"2021-08-01","conditions":["Duration of Hospitalization","Clinical Manifestation of COVID-19"],"enrollment":87,"completionDate":"2021-09-25"},{"nctId":"NCT05185284","phase":"PHASE3","title":"Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2021-08-11","conditions":["COVID-19"],"enrollment":217,"completionDate":"2021-12-30"},{"nctId":"NCT05184127","phase":"PHASE2","title":"Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19","status":"COMPLETED","sponsor":"National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia","startDate":"2021-04-27","conditions":["COVID-19"],"enrollment":156,"completionDate":"2021-09-07"},{"nctId":"NCT04818320","phase":"PHASE3","title":"Favipiravir in High-risk COVID-19 Patients","status":"COMPLETED","sponsor":"Penang Hospital, Malaysia","startDate":"2021-02-16","conditions":["Covid19"],"enrollment":500,"completionDate":"2021-07-13"},{"nctId":"NCT04373733","phase":"PHASE3","title":"Early Intervention in COVID-19: Favipiravir Verses Standard Care","status":"COMPLETED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2020-05-01","conditions":["Coronavirus Infection"],"enrollment":502,"completionDate":"2021-06-25"},{"nctId":"NCT04464408","phase":"PHASE2,PHASE3","title":"Favipiravir Therapy in Adults With Mild COVID-19","status":"COMPLETED","sponsor":"King Abdullah International Medical Research Center","startDate":"2020-07-23","conditions":["COVID-19"],"enrollment":231,"completionDate":"2021-08-04"},{"nctId":"NCT04351295","phase":"PHASE2,PHASE3","title":"Efficacy of Faviprevir in COVID-19 Treatment","status":"COMPLETED","sponsor":"Tanta University","startDate":"2020-04-20","conditions":["COVID"],"enrollment":92,"completionDate":"2020-09-28"},{"nctId":"NCT04387760","phase":"PHASE2","title":"Favipiravir vs Hydroxychloroquine vs Control in COVID -19","status":"COMPLETED","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2020-08-11","conditions":["SARS-CoV 2","COVID-19"],"enrollment":150,"completionDate":"2021-04-07"},{"nctId":"NCT04445467","phase":"PHASE2","title":"An Adaptive Clinical Trial of Antivirals for COVID-19 Infection","status":"UNKNOWN","sponsor":"Bayside Health","startDate":"2020-07-30","conditions":["COVID"],"enrollment":190,"completionDate":"2021-12"},{"nctId":"NCT04303299","phase":"PHASE3","title":"Fight COVID-19 Trial","status":"COMPLETED","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2020-08-19","conditions":["SARS-COV-2 Infections","COVID-19"],"enrollment":320,"completionDate":"2021-08-28"},{"nctId":"NCT05014373","phase":"PHASE3","title":"Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19","status":"UNKNOWN","sponsor":"University of the Philippines","startDate":"2020-10-12","conditions":["Covid19"],"enrollment":144,"completionDate":"2021-08-31"},{"nctId":"NCT04392973","phase":"NA","title":"FAvipiravir and HydroxyChloroquine Combination Therapy","status":"COMPLETED","sponsor":"King Abdullah International Medical Research Center","startDate":"2020-05-21","conditions":["COVID19"],"enrollment":268,"completionDate":"2021-04-26"},{"nctId":"NCT04981379","phase":"PHASE3","title":"Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2020-11-16","conditions":["Covid19"],"enrollment":1120,"completionDate":"2021-02-16"},{"nctId":"NCT04932889","phase":"","title":"Musculoskeletal Symptoms in Post Acute Covid-19 Patients","status":"COMPLETED","sponsor":"Eskisehir City Hospital","startDate":"2021-06-11","conditions":["Covid19","Musculoskeletal Abnormalities"],"enrollment":280,"completionDate":"2021-06-14"},{"nctId":"NCT04828564","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19","status":"UNKNOWN","sponsor":"The Scientific and Technological Research Council of Turkey","startDate":"2021-04","conditions":["SARS-CoV2","COVID-19"],"enrollment":100,"completionDate":"2021-12-31"},{"nctId":"NCT04474457","phase":"","title":"Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age","status":"UNKNOWN","sponsor":"Ministry of Health, Turkey","startDate":"2020-06-11","conditions":["COVID-19"],"enrollment":1000,"completionDate":"2021-06-01"},{"nctId":"NCT04411433","phase":"PHASE3","title":"Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19","status":"UNKNOWN","sponsor":"Ministry of Health, Turkey","startDate":"2020-05-08","conditions":["Sars-CoV2","COVID-19"],"enrollment":1008,"completionDate":"2021-06-01"},{"nctId":"NCT04646109","phase":"PHASE3","title":"Ivermectin for Severe COVID-19 Management","status":"COMPLETED","sponsor":"Afyonkarahisar Health Sciences University","startDate":"2020-05-11","conditions":["COVID-19"],"enrollment":66,"completionDate":"2020-09-02"},{"nctId":"NCT04715360","phase":"PHASE1,PHASE2","title":"Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy","status":"UNKNOWN","sponsor":"Hayandra Peduli Foundation","startDate":"2020-12-29","conditions":["Covid19","Sars-CoV-2 Infection","ARDS, Human","Severe covid19"],"enrollment":30,"completionDate":"2021-12-27"},{"nctId":"NCT04694612","phase":"PHASE3","title":"Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal","status":"UNKNOWN","sponsor":"Nepal Health Research Council","startDate":"2021-01-01","conditions":["Covid19"],"enrollment":676,"completionDate":"2021-05-31"},{"nctId":"NCT04651959","phase":"PHASE1","title":"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Pharma Plant, Turkey) Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharma Plant","startDate":"2020-11-13","conditions":["Bioequivalence"],"enrollment":30,"completionDate":"2020-12-20"},{"nctId":"NCT04444986","phase":"PHASE1","title":"Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions","status":"COMPLETED","sponsor":"Kocak Farma","startDate":"2020-06-05","conditions":["Bioequivalence"],"enrollment":30,"completionDate":"2020-06-13"},{"nctId":"NCT04645433","phase":"","title":"Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit","status":"COMPLETED","sponsor":"Sisli Hamidiye Etfal Training and Research Hospital","startDate":"2020-03-15","conditions":["Mortality","Intensive Care Unit"],"enrollment":100,"completionDate":"2020-05-15"},{"nctId":"NCT04542694","phase":"PHASE3","title":"Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Promomed, LLC","startDate":"2020-05-21","conditions":["COVID-19"],"enrollment":200,"completionDate":"2020-08-20"},{"nctId":"NCT04558463","phase":"PHASE3","title":"The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19","status":"UNKNOWN","sponsor":"Indonesia University","startDate":"2020-04-16","conditions":["Covid19"],"enrollment":100,"completionDate":"2020-10-30"},{"nctId":"NCT04478448","phase":"PHASE1","title":"Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2020-08-13","conditions":["Healthy"],"enrollment":26,"completionDate":"2020-08-26"},{"nctId":"NCT04527133","phase":"NA","title":"An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19","status":"UNKNOWN","sponsor":"Aviron LLC","startDate":"2020-06-11","conditions":["COVID-19"],"enrollment":30,"completionDate":"2020-08-31"},{"nctId":"NCT04406194","phase":"PHASE1","title":"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions","status":"COMPLETED","sponsor":"Atabay Kimya Sanayi Ticaret A.S.","startDate":"2020-05-14","conditions":["Bioequivalence"],"enrollment":30,"completionDate":"2020-06-19"},{"nctId":"NCT04407000","phase":"PHASE1","title":"Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions","status":"COMPLETED","sponsor":"World Medicine ILAC SAN. ve TIC. A.S.","startDate":"2020-06-23","conditions":["Bioequivalence"],"enrollment":30,"completionDate":"2020-08-08"},{"nctId":"NCT04400682","phase":"PHASE1","title":"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions","status":"COMPLETED","sponsor":"Novelfarma Ilaç San. ve Tic. Ltd. Sti.","startDate":"2020-05-28","conditions":["Bioequivalence"],"enrollment":30,"completionDate":"2020-06-18"},{"nctId":"NCT04349241","phase":"PHASE3","title":"Efficacy and Safety of Favipiravir in Management of COVID-19","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-04-18","conditions":["Coronavirus Disease (COVID-19)"],"enrollment":100,"completionDate":"2020-06-20"},{"nctId":"NCT04434248","phase":"PHASE2,PHASE3","title":"An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Chromis LLC","startDate":"2020-04-23","conditions":["COVID-19"],"enrollment":330,"completionDate":"2020-07"},{"nctId":"NCT04376814","phase":"NA","title":"Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19","status":"COMPLETED","sponsor":"Baqiyatallah Medical Sciences University","startDate":"2020-03-29","conditions":["COVID-19","Favipiravir","Kaletra","Hydroxychloroquine","Lopinavir/Ritonavir"],"enrollment":40,"completionDate":"2020-05-25"},{"nctId":"NCT04425460","phase":"PHASE3","title":"A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19","status":"UNKNOWN","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2020-06","conditions":["COVID-19"],"enrollment":256,"completionDate":"2020-09"},{"nctId":"NCT04403477","phase":"PHASE2","title":"Convalescent Plasma Therapy in Severe COVID-19 Infection","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2020-05-20","conditions":["Covid19","Convalescence"],"enrollment":20,"completionDate":"2020-10-30"},{"nctId":"NCT04402203","phase":"PHASE2,PHASE3","title":"Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh","status":"UNKNOWN","sponsor":"Bangladesh Medical Research Council (BMRC)","startDate":"2020-05","conditions":["COVID-19","Favipiravir (Favipira)"],"enrollment":50,"completionDate":"2020-07"},{"nctId":"NCT04359615","phase":"PHASE4","title":"Favipiravir in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-20","conditions":["COVID-19"],"enrollment":40,"completionDate":"2020-05-05"},{"nctId":"NCT04333589","phase":"NA","title":"Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2020-04-01","conditions":["COVID-19"],"enrollment":210,"completionDate":"2020-09-15"},{"nctId":"NCT04310228","phase":"NA","title":"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019","status":"UNKNOWN","sponsor":"Peking University First Hospital","startDate":"2020-03-08","conditions":["COVID-19"],"enrollment":150,"completionDate":"2020-05"},{"nctId":"NCT04336904","phase":"PHASE3","title":"Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19","status":"UNKNOWN","sponsor":"Giuliano Rizzardini","startDate":"2020-03-25","conditions":["COVID-19"],"enrollment":100,"completionDate":"2020-07"},{"nctId":"NCT04319900","phase":"PHASE2,PHASE3","title":"Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2020-03-05","conditions":["Novel Coronavirus Pnuemonia"],"enrollment":150,"completionDate":"2020-06-25"},{"nctId":"NCT03394209","phase":"PHASE2","title":"A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2018-02-06","conditions":["Influenza, Human","Critical Illness","Influenza"],"enrollment":34,"completionDate":"2019-03-27"},{"nctId":"NCT02662855","phase":"PHASE2","title":"Efficacy of Favipiravir Against Severe Ebola Virus Disease","status":"COMPLETED","sponsor":"Beijing Institute of Pharmacology and Toxicology","startDate":"2014-11","conditions":["Ebola Virus Disease"],"enrollment":77,"completionDate":"2015-05"},{"nctId":"NCT01068912","phase":"PHASE2","title":"Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza","status":"COMPLETED","sponsor":"MDVI, LLC","startDate":"2010-02","conditions":["Influenza"],"enrollment":530,"completionDate":"2012-05"},{"nctId":"NCT02008344","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults","status":"COMPLETED","sponsor":"MDVI, LLC","startDate":"2013-12","conditions":["Influenza"],"enrollment":1161,"completionDate":"2015-01"},{"nctId":"NCT02026349","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316","status":"COMPLETED","sponsor":"MDVI, LLC","startDate":"2014-01","conditions":["Influenza"],"enrollment":860,"completionDate":"2015-03"},{"nctId":"NCT01419457","phase":"PHASE1","title":"Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment","status":"COMPLETED","sponsor":"MDVI, LLC","startDate":"2011-08","conditions":["Healthy","Hepatic Impairment"],"enrollment":36,"completionDate":"2013-02"},{"nctId":"NCT01728753","phase":"PHASE1,PHASE2","title":"T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza","status":"COMPLETED","sponsor":"MDVI, LLC","startDate":"2012-11","conditions":["Influenza"],"enrollment":550,"completionDate":"2013-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"018626","UNII":"EW5GL2X7E0","CHEBI":"CHEBI:134722","INN_ID":"8916","UMLSCUI":"C1138226","chemblId":"CHEMBL221722","ChEMBL_ID":"CHEMBL221722","KEGG_DRUG":"D09537","DRUGBANK_ID":"DB12466","PUBCHEM_CID":"492405","SNOMEDCT_US":"1163580005","IUPHAR_LIGAND_ID":"11139","MESH_SUPPLEMENTAL_RECORD_UI":"C462182"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Toyama Chemical Co., Ltd.","relationship":"Current Owner"}],"publicationCount":1557,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"J05AX27","allCodes":["J05AX27"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Toyama Chemical Co., Ltd.","companyId":"toyama-chemical-co-ltd","modality":"Small molecule","firstApprovalDate":"2014","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2014-03-24T00:00:00.000Z","mah":"Toyama Chemical Co., Ltd.","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:33:09.812987+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}